University of PittsburghUniversity of Pittsburgh
Startups
TechnologiesStartupsExpress LicensesCollectionsChat with AI
Sign in
University of Pittsburgh

Rezq Bio, Inc.

OverviewRequest InfoMore Like ThisExpress Licenses

Sector

Therapeutics

Therapeutic Areas

ImmunologyEndocrinology and Metabolic Diseases

Funding Stage

Seed

Founders

Arjun HattiangadiNick GiannoukakisMassimo TruccoDavid Finegold

Website

https://www.rezq.bio/
Rezq Bio, Inc.

Rezq Bio is developing therapies designed to restore immune tolerance, beginning with type 1 diabetes. Its lead program uses a patient’s own dendritic cells to address the immune response that attacks healthy tissue. The company is preparing this investigational therapy for Phase 1b/2a development and exploring microsphere-based delivery for broader applications. [1]

The Pittsburgh company’s scientific foundation includes University of Pittsburgh diabetes research and co-founder David Finegold’s clinical expertise. Its pipeline also explores localized treatment for inflammatory bowel disease and protection of transplanted cells, with the goal of reducing reliance on broad immune suppression. [2] [1]

Discover More with AI